All the Active Ingredient Drugs
Anthracycline. Doxorubicin (HCl) 2 mg/ml. I.V. INFUS. (liposome inject.): 1. Ovarian
cancer: 50 mg/m2 I.V at initial rate of 1
mg/min. Incr. rate if no infus. related
AE’s observed over 1 hr., every 4 wks.
for as long as pt. does not progress,
shows no signs cardiotox. and cont. tol.
to tmt. 4 courses recommend. See lit.
AIDS KS: 20 mg/m2 I.V. over 30 mins.
once every 3 wks as long as pt.
tolerates and responds.
Monother. in metastat. breast cancer,
where there is incr. cardiac risk. 1st or 2nd
line ther. of AIDS-related Kaposis sarcoma in pts. with low cd 4 counts and extens. mucocutan. or visc. dis. Tmt. of pts with metastat. carcinoma of the ovary who are refract. to both paclitaxel and platinumbased chemother. regimens and who may also be refract. to topotecan. Refract. is defined as a pt. having progress. dis. while on tmt., or within 6 mths of completing tmt.
Anthracycline. Doxorubicin HCl 2 mg/ml. VIALS (sol. for inject.): 25 ml, 100 ml.
Recommend. total dose: 550 mg/m² I.V.
See lit. Recommend. schedule: 60-75
mg/m² as single I.V. at 21-day intervals.
To produce regress. in dissem. neoplastic
conds. e.g. acute lymphoblast. leuk., acute
myeloblast. leuk., Wilms’ tumor, nblast.,
soft tissue/bone sarc., carc. breast, ovary,
transient cell bladder carc., thyroid carc.,
lymph of both Hodgkin’s and non-
Hodgkin’s bronchogen. carc., gastr. carc.